Home Drug reform Page 4

Keyword: Drug reform

162 results found
What tools can employers use to address employees’ sleep concerns?

While insomnia is a disorder, it’s just as commonly a symptom, which most people and physicians don’t grasp, said Dr. Atul Khullar, medical director at the Northern Alberta Sleep Clinic. A lot of times, not sleeping is essentially the body breaking down because of a separate disorder, risk factor or residual symptom of a mental-health […]

Conference coverage: 2019 Face to Face Drug Plan Management Forum

On Dec. 3, the 2019 Face to Face Drug Plan Management Forum featured sessions on rare disease, the pharmaceutical industry’s point of view, legal obligations in drug plan management and a deeper dive into drug programs. Capping coverage for plan members with rare diseases poses an ethical dilemma While high-cost specialty medications represent about 30 […]

Is innovation causing accessibility, timing issues for private drug plans?

Pharmaceutical companies and private payers can interact in different ways to ensure the right drugs are getting to the right patients, according to Kathy Sotirakos, senior manager of market access and private insurance at Amgen. Real world evidence will help inform better decision-making from a predictability and outcomes perspective, she said during a panel at […]

Collaboration fundamental when managing, altering private drug plans

As the landscape of Canadian drug plan management continues to evolve, several programs are being implemented by insurers and pharmacy benefits managers to help plan sponsors manage costs. Speaking on a panel at Benefits Canada’s 2019 Face to Face Drug Plan Management Forum on Dec. 3 in Toronto, Ned Pojskic, leader of pharmacy and health provider […]

Draft PMPRB guidelines include changes to reference countries, drug price factors

The Patented Medicine Prices Review Board has published draft guidelines, including new factors for setting patented drug prices and an updated list of reference countries for Canada to compare its prices. The guidelines were updated to address the federal government’s final amendments to the PMPRB rules, which were released in August. The board is seeking comment from stakeholders until Jan. 20, […]

  • By: Staff
  • November 25, 2019 November 12, 2020
  • 09:15
Proposed changes to Ontario drug rules target generics pricing, biosimilar listing process

Ontario has proposed amendments to provincial drug regulations that aim to change the pricing model for generic drugs and simplify the process for the province’s drug formulary to list biosimilars. Ontario’s Ministry of Health and Long-Term Care said the changes are aimed at reducing the “administrative burden” for drug manufacturers and pharmacies. With regards to […]

  • By: Staff
  • November 14, 2019 November 12, 2020
  • 09:00

The Alberta Teachers’ Retirement Fund Board will transfer all of its funds to the Alberta Investment Management Corp., according to the province’s latest budget. The ATRF board, which administers pensions for all teachers in Alberta school jurisdictions and charter schools, said in a press release it was only made aware of the change when the budget was released […]

Editorial: Looking back — and ahead — in an unprecedented year

It’s an election year and, of course, I have a lot of opinions. But I’ll try to keep my political leanings as neutral as possible and simply lay out the facts. This issue will hit desks days before the federal election. However, as I write these words in mid-September, the main parties are just rolling […]

Liberals pledging to boost investments in mental health, pharmacare

The Liberal Party of Canada is promising a number of health-care reforms in its election platform, including a national pharmacare program and improved access to mental-health services. According to a backgrounder document, the Liberals are aiming to “strengthen the Canada Health Act to make sure the full range of mental-health services required by Canadians are available in every […]

  • By: Staff
  • September 24, 2019 November 12, 2020
  • 09:30
Institutional investors urging Congress to vote down CUSMA, citing effect on drug prices

A group of institutional investors representing more than US$500 billion is calling on the U.S. Congress to vote down the Canada-United States-Mexico trade agreement to prevent extended monopoly rights for pharmaceutical companies in all three countries. The Interfaith Center on Corporate Responsibility, which represents more than 300 religious institutional investors, pension funds, foundations, asset managers […]